Saeed Bohlega Selected Research

Therapeutics

1/2022	Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies.
6/2021	Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.
1/2021	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity.
6/2020	Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.
4/2018	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy.
1/2017	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
1/2016	Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.
1/2015	Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
9/2014	Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations.
4/2014	Oromandibular dystonia in yemeni patients with khat chewing: a response to botulinum toxin treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Saeed Bohlega Research Topics

Disease

4	Dystonia (Limb Dystonia) 09/2023 - 06/2006
4	Dyskinesias (Dyskinesia) 11/2016 - 04/2003
3	Woodhouse Sakati syndrome 09/2023 - 12/2008
3	Parkinson Disease (Parkinson's Disease) 01/2022 - 10/2006
3	Movement Disorders (Movement Disorder) 04/2018 - 01/2015
3	Multiple Sclerosis 01/2017 - 11/2007
2	Myoclonic Epilepsies (Myoclonic Encephalopathy) 09/2023 - 05/2002
2	COVID-19 11/2021 - 06/2021
2	Relapsing-Remitting Multiple Sclerosis 09/2021 - 06/2020
2	Stroke (Strokes) 01/2017 - 10/2009
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2012 - 12/2011
2	CADASIL 05/2008 - 11/2007
1	X-Linked Torsion Dystonia 3 09/2023
1	Familial paroxysmal dystonia 09/2023
1	Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy) 09/2023
1	Chorea (Rheumatic Chorea) 01/2023
1	Parkinsonian Disorders (Parkinsonism) 01/2022
1	Poisoning 01/2022
1	Tremor (Tremors) 01/2022
1	Intracranial Vasospasm 01/2022
1	Infections 06/2021
1	Hereditary Spastic Paraplegia 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2016
1	Spontaneous Abortion (Miscarriage) 01/2016
1	Glycogen Storage Disease Type II (Pompe's Disease) 10/2015
1	Headache (Headaches) 09/2014
1	Venous Thrombosis (Deep-Vein Thrombosis) 09/2014
1	Juvenile Amyotrophic Lateral Sclerosis 2 10/2012
1	Chronic Disease (Chronic Diseases) 04/2010
1	MELAS Syndrome (Syndrome, MELAS) 10/2009
1	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2007
1	Alopecia (Baldness) 01/2007
1	Diabetes Mellitus 01/2007
1	Deafness (Deaf Mutism) 01/2007
1	Hypokinesia (Bradykinesia) 10/2006
1	Lafora Disease 10/2003
1	Epilepsy (Aura) 10/2003
1	Seizures (Absence Seizure) 04/2003
1	Atrophy 04/2003
1	Abnormal Reflex (Hyperreflexia) 04/2003

Drug/Important Bio-Agent (IBA)

5	Botulinum Toxins (Botulinum Toxin)IBA 01/2022 - 04/2014
3	Levodopa (L Dopa)FDA LinkGeneric 01/2022 - 10/2006
2	IronIBA 01/2022 - 05/2016
2	Cladribine FDA LinkGeneric 09/2021 - 06/2021
2	TabletsIBA 09/2021 - 06/2021
2	Type A Botulinum Toxins (Botox)FDA Link 11/2016 - 04/2014
2	Mitochondrial DNA (mtDNA)IBA 10/2009 - 05/2008
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 09/2023
1	Protein AggregatesIBA 01/2023
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2022
1	Methanol (Carbinol)IBA 01/2022
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2022
1	PerfumeIBA 01/2022
1	Dopamine Agents (Dopaminergic Agents)IBA 01/2022
1	VaccinesIBA 11/2021
1	Alemtuzumab (Campath)FDA Link 06/2021
1	teriflunomideIBA 06/2021
1	Natalizumab (Tysabri)FDA Link 06/2021
1	Fingolimod Hydrochloride (FTY720)FDA Link 06/2021
1	Dimethyl FumarateIBA 06/2021
1	Interferon-betaIBA 06/2021
1	siponimodIBA 06/2021
1	ocrelizumabIBA 06/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019
1	InterferonsIBA 01/2016
1	EnzymesIBA 10/2015
1	alpha-Glucosidases (Acid Maltase)IBA 10/2015
1	GlycogenIBA 10/2015
1	Carbidopa (Lodosyn)FDA LinkGeneric 01/2015
1	LipidsIBA 10/2012
1	Proteins (Proteins, Gene)FDA Link 10/2012
1	Sigma-1 ReceptorIBA 12/2011
1	DNA (Deoxyribonucleic Acid)IBA 10/2009
1	Nuclear Proteins (Protein, Nuclear)IBA 12/2008
1	Epidermal Growth Factor (EGF)IBA 11/2007
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2007
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2007
1	Testosterone (Sustanon)FDA Link 01/2007
1	PTEN-induced putative kinaseIBA 10/2006
1	polyglucosanIBA 10/2003
1	Lipoproteins (Lipoprotein)IBA 04/2003
1	Dual-Specificity PhosphatasesIBA 05/2002

Therapy/Procedure

13	Therapeutics 01/2022 - 10/2006
2	Injections 01/2021 - 11/2016
1	Pallidotomy 06/2006
1	Deep Brain Stimulation 06/2006